Harris A, McIntyre N
Br J Clin Pharmacol. 1981; 12(2):254-5.
PMID: 7306441
PMC: 1401853.
DOI: 10.1111/j.1365-2125.1981.tb01212.x.
Evans D
J Med Genet. 1984; 21(4):243-53.
PMID: 6387123
PMC: 1049291.
DOI: 10.1136/jmg.21.4.243.
Azad Khan A, Howes D, Piris J, TRUELOVE S
Gut. 1980; 21(3):232-40.
PMID: 6105118
PMC: 1420362.
DOI: 10.1136/gut.21.3.232.
Porter A
Br Med J. 1968; 2(5602):406-7.
PMID: 5649002
PMC: 1985963.
DOI: 10.1136/bmj.2.5602.406.
Mattila M
Humangenetik. 1970; 9(3):212-4.
PMID: 5311191
DOI: 10.1007/BF00279217.
Multiple N-acetyltransferases and drug metabolism. Tissue distribution, characterization and significance of mammalian N-acetyltransferase.
Hearse D, Weber W
Biochem J. 1973; 132(3):519-26.
PMID: 4724587
PMC: 1177616.
DOI: 10.1042/bj1320519.
The relationship between response to phenelzine and acetylator status in depressed patients.
Johnstone E, Marsh W
Proc R Soc Med. 1973; 66(9):947-9.
PMID: 4616245
PMC: 1645414.
Variability in response to drugs.
Rawlins M
Br Med J. 1974; 4(5936):91-4.
PMID: 4607336
PMC: 1612144.
DOI: 10.1136/bmj.4.5936.91.
Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects.
Schroder H, Evans D
Gut. 1972; 13(4):278-84.
PMID: 4402420
PMC: 1412167.
DOI: 10.1136/gut.13.4.278.
Editorial: New vasodilator drugs for hypertension.
Br Med J. 1973; 4(5886):185-6.
PMID: 4148460
PMC: 1587294.
DOI: 10.1136/bmj.4.5886.185.
N2-acetylphenelzine: effects on rat brain GABA, alanine and biogenic amines.
McKenna K, Baker G, Coutts R
Naunyn Schmiedebergs Arch Pharmacol. 1991; 343(5):478-82.
PMID: 1881457
DOI: 10.1007/BF00169549.
The myth of phenelzine acetylation.
Marshall E
Br Med J. 1976; 2(6039):817.
PMID: 974644
PMC: 1688643.
DOI: 10.1136/bmj.2.6039.817.
The relationship between acetylator status and inhibition of monoamine oxidase, excretion of free drug and antidepressant response in depressed patients on phenelzine.
Johnstone E
Psychopharmacologia. 1976; 46(3):289-94.
PMID: 951464
DOI: 10.1007/BF00421116.
Polymorphic acetylation of nitrazepam.
Karim A, Evans D
J Med Genet. 1976; 13(1):17-9.
PMID: 775091
PMC: 1013342.
DOI: 10.1136/jmg.13.1.17.
Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype.
Carr K, OATES J, Nies A, Woosley R
Br J Clin Pharmacol. 1978; 6(5):421-7.
PMID: 728285
PMC: 1429553.
DOI: 10.1111/j.1365-2125.1978.tb04606.x.
N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark.
Lower Jr G, Nilsson T, Nelson C, Wolf H, Gamsky T, Bryan G
Environ Health Perspect. 1979; 29:71-9.
PMID: 510245
PMC: 1637362.
DOI: 10.1289/ehp.792971.
Phenelzine: acetylator status and clinical response.
Sanders G, Rawlins M
Br J Clin Pharmacol. 1979; 7(5):451-2.
PMID: 475942
PMC: 1429579.
DOI: 10.1111/j.1365-2125.1979.tb00985.x.
Recent advances in antidepressant drug treatment.
Ericksen S
West J Med. 1979; 131(2):104-13.
PMID: 390888
PMC: 1271701.
The influence of acetylator phenotype on the outcome of treatment with phenelzine, in a clinical trial.
Marshall E, Mountjoy C, Campbell I, Garside R, Leitch I, Roth M
Br J Clin Pharmacol. 1978; 6(3):247-54.
PMID: 356868
PMC: 1429446.
DOI: 10.1111/j.1365-2125.1978.tb04593.x.
Some of the problems and difficulties associated with clinical studies of antidepressant agents.
Jenner F
Br J Clin Pharmacol. 1977; 4Suppl 2:199S-207S.
PMID: 334224
PMC: 1429100.
DOI: 10.1111/j.1365-2125.1977.tb05753.x.
